Full Library
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial
Resource type
Journal Article
Authors/contributors
- de Jonge, Nick A (Author)
- Sikkens, Jonne J (Author)
- Zweegman, Sonja (Author)
- Beeker, Aart (Author)
- Ypma, Paula (Author)
- Herbers, Alexandra H (Author)
- Vasmel, Wies (Author)
- de Kreuk, Arne (Author)
- Coenen, Juleon L L M (Author)
- Lissenberg-Witte, Birgit (Author)
- Kramer, Mark H H (Author)
- van Agtmael, Michiel A (Author)
- Janssen, Jeroen J W M (Author)
Title
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial
Publication
The Lancet Haematology
Date
6/2022
Pages
S2352302622001454
Journal Abbr
The Lancet Haematology
Accessed
6/17/22, 12:03 PM
ISSN
23523026
Short Title
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia
Language
en
Library Catalog
DOI.org (Crossref)
Citation
de Jonge, N. A., Sikkens, J. J., Zweegman, S., Beeker, A., Ypma, P., Herbers, A. H., Vasmel, W., de Kreuk, A., Coenen, J. L. L. M., Lissenberg-Witte, B., Kramer, M. H. H., van Agtmael, M. A., & Janssen, J. J. W. M. (2022). Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial. The Lancet Haematology, S2352302622001454. https://doi.org/10.1016/S2352-3026(22)00145-4
HEME-ONC AND CELLULAR THERAPIES
Link to this record